Earnings

LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 Est; Narrows FY2026 Sales Guidance from $274.300M-$278.300M to $274.800M-$276.800M vs $276.539M Est

Nov 4, 2026 · 04:24 PM ET· updated 1h ago

LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 analyst estimate. Narrows FY2026 sales outlook from $274.300 million-$278.300 million to $274.800 million-$276.800

Why It Matters

LeMaitre Vascular cut its profit forecast for next year. The company now expects less money to come in than people thought.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LMAT77.05

-3.55 (-4.40%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.